Preliminary results in secondary acute non-lymphocytic leukemia (ANLL) treated with Idarubicin.
The results of Idarubicin treatment in patients with secondary acute non-lymphocytic leukemia are presented: 7 courses have been performed in 6 patients and 4 complete remissions have been induced in three of them. Tolerance was excellent and no cardiotoxicity was observed. However, remissions were short and combination therapy is suggested.
D000328:Adult; D000368:Aged; D003630:Daunorubicin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D015255:Idarubicin; D007938:Leukemia / Q000188:drug therapy*; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local
D015255:Idarubicin; D003630:Daunorubicin